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Abstract The lipocalin apolipoprotein D (ApoD) is associated 
in human plasma with lecithin-cholesterol acyl transferase. It has 
also been found in high concentration in the fluid of gross cystic 
disease of the mammary gland. Using protein fluorescence 
quenching, it is shown that ApoD binds arachidonic acid (K, of 
1.6 x 10 s M -~) and as previously known progesterone (Ka of 
2.5 x 10 6 M-~), but neither cholesterol nor any of the other pro- 
stanoid molecules examined had measurable affinity. This spe- 
cific binding of arachidonate, also observable directly, suggests 
a role for ApoD in the mobilisation of arachidonic acid, and hence 
prostaglandin synthesis. 
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I. Introduction 
Apolipoprotein D (ApoD) is a member of the lipocalin struc- 
tural family. Despite a low degree of  sequence homology the 
member proteins share a highly similar fold and an affinity for 
small hydrophobic molecules [1-3]. The function of this protein 
is unknown but it has been shown to be involved in a number 
of apparently unrelated biological situations. In the plasma, 
this protein is associated with apolipoprotein A-I and lecithin- 
cholesterol acyltransferase (LCAT) forming along with other 
components, the high density lipoproteins (HDL) [4,5]. ApoD 
has also been found in the fluid of cysts formed during mam- 
mary gross-cystic disease [6], where it is the major protein 
component. The cyst fluid is rich in many different steroid 
hormones at concentrations that can reach values up to 100 
times higher than in plasma [7]. Whilst ApoD binds several of 
these steroids, it demonstrates a particular affinity for proges- 
terone and pregnenolone but none at all for cholesterol [8,9]. 
The production of protein has also been detected during 
some growth or regeneration processes. In particular, during 
the regeneration of peripheral nervous tissue in the rat [10], 
where it was observed that the basal levels of ApoD and apol- 
ipoprotein E increase several fold. Also, during steroid modu- 
lated growth of some cancer cell lines (breast lines ZR-75, 
MCF-7, T37-D [11-13] and prostate LNCaP [14]) production 
of ApoD presents a biphasic pattern. In both situations, the 
ApoD level was increased when the cell multiplication stopped. 
Further, in normal human diploid fibroblast cell lines, ApoD 
is secreted when cells have reached a senescent stage [15]. The 
* Corresponding author. Fax: (44) (131) 650 3711. 
E-mail: L.Sawyer@ac.ed.uk 
properties and the possible functions of ApoD have recently 
been fully reviewed by Milne et al. [16] and Flower [17]. 
We report here a study of the binding of a variety of ligands 
to ApoD and the identification of a high affinity for ara- 
chidonic acid, leading to a proposal for the function of the 
protein which could relate the presence of  the protein in gross 
cystic disease, its association with LCAT in blood plasma and 
in the secretions from some cancer cells. 
2. Materials and methods 
2.1. Protein purificatio,~ 
ApoD was purified from gross-cystic disease fluid (GCDF) by a 
modification of the published method [6]. The fluid was obtained from 
patients either at the Hospital de Jove, Gijon (Asturias), or from the 
Breast Clinic, Edinburgh Royal Infirmary. Several batches of GCDF 
were spun at 4°C for 1 h (30,000 rpm, Beckman rotor 50Ti) to pellet 
cell debris. The supernatant was concentrated 5-fold and 0.5-0.8 ml of 
the concentrate were loaded onto a preparative gel filtration column 
(Beckman TSK300SWG 21.5 x 300 mm, precolumn Beckman Sphero- 
gel 7.5 × 75 ram) attached to a Waters HPLC system, equilibrated and 
eluted at 0.2 ml.min -~ with 0.1 M ammonium acetate, pH 6. A further 
step, based upon ApoD purification from plasma [18] was introduced 
to achieve higher purity. Fractions found to contain ApoD were 
pooled, dialysed against 1 mM KzHPO4, pH 8, and loaded onto a 
2.6 × 70 cm hydroxyapatite column (BioRad) equilibrated with the 
same buffer. Protein contaminants were retained by the column and 
ApoD was eluted at a flow rate of 40 ml/h with the loading buffer. 
Analysis of the protein preparations by SDS-PAGE and by Western 
blotting, showed that the ApoD was effectively free from contaminat- 
ing material. 
2.2. Ligand-binding experiments 
The ligand-binding experiments were performed at 25 + 0.1°C with 
a Parker-Elmer Luminescence Spectrometer L-50 with slits set at 5 nm 
bandwidth, the sample xcited at 280 nm and the emission recorded at 
340 nm (the wavelength of maximum emission for the protein under 
these conditions). 50 mM KHzPO4 buffer, pH 7.0, was used throughout 
and the ethanol used for dissolving the ligands was of chromatographic 
grade (Rathburn). To correct for the inner filter effect [19], the titration 
of N-acetyl-tryptophanamide (Sigma) with each ligand and ethanol was 
measured under the same conditions as the protein with the absorbance 
at 280 nm adjusted to equal that of the protein. 
All of the titrations were performed with protein isolated from a 
single pool of cyst fluid (8 patients). The protein (in a weakly buffered 
stock solution) was diluted to 2.0 x 10 -6 M (e = 32,320 M Lem ' [20]). 
Ligands (100 #M in ethanol) were added to the protein solution in 2 
or 4 #1 aliquots to a total of 40 #1. For each ligand, three independent 
titrations were performed and a standard eviation estimated. A base 
line for the effect of the ethanol on the fluorescence of ApoD was 
produced by titrating the protein with ethanol, and the emission spectra 
were recorded at different stages of the titration. The measurements 
were corrected for protein concentration a d averaged between assays 
for the same ligand before finally having the ethanol baseline (corrected 
and averaged as for the protein titrations) subtracted. These values were 
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then further corrected if the Nacetyl-tryptophanamide t trations 
showed significant inner filter effect. 
The ligands used were the following: progesterone (4-pregene-3,20- 
dione), cholesterol (5-cholesten-3fl-ol), prostaglandin E1 
((llc~,13E,15S)-ll,15-dihydroxy-9-oxoprosta-13-enoic acid), prosta- 
glandin F2a ((5Z,9cd Ia,13E,15S)-9,11,15-trihydroxy-prosta-5,15- di- 
enoic acid), prostaglandin D2 ((5Z,9~,13E, I 5S)-9,15-dihydroxy-11- 
oxoprosta-5,13-dien-l-oic acid), arachidonic acid (eicosa=5Z,8Z, 
1 IZ, 14Z-tetraenoic a id), palmitic acid (hexadecanoic a id), DPPC (L- 
~-dipalmitoyl phosphatidyl choline) all from Sigma. 12-HETE (12- 
hydroxy-[S-(E,Z,Z,Z)]-5,8,10,14-eicosatetraenoic cid), 5,15-diHETE 
(5,15-dihydroxy-[S-[R*,R*-(E,E,Z,Z)]]-6,8,11,13-eicosatetraenoic acid, 
linoleic acid (octadeca-9Z,8Z, 11Z, 14Z-tetraenoic a id), oleic acid (oc- 
tadeca-9Z-enoic acid) from Cascade Biochem, Reading. EP092 ((_+ 5)- 
endo-(6'-carboxyhex-2"Z-enyl)-6-exo- { 1-[(N-phenylthiocarbamoyl)- 
hydrazono]-ethyl}bicyclo[2.2.1]heptane [21] was provided by Drs. 
Wilson and Jones from the Department of Pharmacology, University 
of Edinburgh. 
2.3. Analysis of b&ding 
A model of random binding to an unknown umber of homogeneous 
sites was fitted using weighted nonlinear regression of F (the corrected 
fluorescence) versus [L]t (total igand concentration) with Fma~, Kd and 
[P]t (ligand binding site concentration) as the three parameters to be 
estimated. Weights were either unity or the inverse variance. The pro- 
gram for model fitting is written in C and will be described elsewhere. 
Data extracted from Figure 6 of Dilley et al. [9], where progesterone 
binding was determined using gel filtration gave values very similar to 
the ones presented in that report, confirming the validity of the chosen 
model. 
3. Results 
The ethanol used to dissolve the ligands, was observed to 
quench the fluorescence of ApoD (data not shown). Ethanol 
is known to perturb the structure of another member of the 
lipocalin family [22] and in order to eliminate protein confor- 
mational changes as a reason for quenching, the following 
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Fig. 1. Titration curves for ApoD from gross cystic disease fluid with 
progesterone (open squares), cholesterol (triangles) and arachidonic 
acid (closed squares). The ligand concentration was 100/zM. Typical 
error bars for all three titration curves are shown on one of the curves 
only. 
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Fig. 2. Fit of the corrected ata for ApoD from GCDF with progester- 
one C :) and that calculated from the model assuming an unknown 
number of ligand binding sites of equal affinity (+). 
controls were made. The emission spectra at different ethanol 
concentrations were measured and no wavelength shift of the 
maximum emission was observed with increasing ethanol con- 
centration, indicating that there was no major conformation 
change affecting the solvent-inaccessible fluorescent groups 
(data not shown). The absorbance spectra of ApoD (240-350 
nm), recorded in the presence of ethanol within the concentra- 
tion range 0-4% (v/v), did not reveal any changes besides a rise 
in the overall base line. The CD spectrum of ApoD in the 
presence of 4% ethanol was recorded between 190-260 nm and 
compared to the native spectrum. The spectra were superim- 
posable except for the 190-200 nm range, where the noise was 
clearly greater. Thus, the small increase in derived cz-helix con- 
tent in the presence of ethanol as determined by the CONTIN 
procedure [23] was almost certainly due to the noise increase 
in the far UV range. Taken together, these facts indicate that 
no major conformational change occurs in the range of ethanol 
concentrations to which ApoD was exposed. A correction for 
the small ethanol effect was applied to the ligand titration 
curves by subtraction of the ethanol quenching from the overall 
ethanol/ligand quenching. 
The corrected titration curves for progesterone and cholest- 
erol are shown in Fig. 1. These two molecules erved to test the 
method because it was known that ApoD binds progesterone 
[8,9] tightly but not cholesterol [8]. The marked difference be- 
tween the titration curves, showing that progesterone- 
quenched protein fluorescence reaches saturation while 
cholesterol did not affect the fluorescence at all, demonstrated 
that the method was capable of detecting binding. However, the 
error bars plotted for progesterone were typical and demon- 
strate that the errors in this experimental system were quite 
large. Analysis of the weighted binding data gave a good fit to 
J.H. Morais Cabral et al./FEBS Letters 366 (1995) 53 56 
20 
-20 
Fluorescence 
difference -40. 
-60 • 
-80' 
-100 
: : , , ,  • 
n~ 
• ,=. 
o 
o 
o l l  • • • • 
o a 
o 
jo  
0 
o 
o 
0 
0 o 0 
1'0 2'0 3'0 4'0 50 
Volume of ligand (p.I) 
Fig. 3. Titration curves for the ApoD from GCDF with a variety of 
ligands. Arachidonic acid (filled squares), prostaglandin D2 (filled cir- 
cles), 5,15-diHETE (filled triangles), 12-HETE (open squares), EP092 
(open circles), prostaglandin E1 (open triangles), prostaglandin F2a 
(crosses). The ligand concentration was 100 pM. 
the model (Fig. 2) and produced an association constant of 
2.53( + 0.31) x 106 M -~ similar to the reported values [8,9]. In 
addition, we found that ApoD purified from plasma had a 
similar affinity for progesterone. 
The titration curves of several molecules tested for affinity 
for ApoD (EP092, prostaglandins D2, E 1 and F2a, arachidonic 
acid, 12-HETE, 5,15-diHETE) are presented in Fig. 3. Of these, 
only EP092 (a thromboxane antagonist [21]) and arachidonic 
acid demonstrated significant affinity as judged by the quench- 
ing of ApoD fluorescence. The binding of arachidonate was 
confirmed by Lipidex-based methods [24] and size-exclusion 
HPLC of Apod incubated with radioactive arachidonic acid. 
The amount of arachidonate observed to bind directly was 
comparable to that calculated from the fluorescence data, and 
higher than those observed for other putative ligands for 
ApoD, including progesterone and progestagen derivatives 
(data not shown). 
Finally, of the small series of fatty acids (arachidonic (C20:4), 
linoleic (C18:2), oleic (C18:1) and palmitic (C16:0)) and one 
phospholipid (dipalmitoyl phosphatidyl choline) tested, only 
arachidonic acid showed any affinity for ApoD. The associa- 
tion constant determined for arachidonic acid was 
1.62( + 1.06) x 108 M -1 with the observed weights applied. 
4. D iscuss ion  
Fluorescence spectroscopy was chosen for this study because 
it is a technique which has already been used for ligand-binding 
studies with other lipocalins [25,26]. We have shown that ar- 
achidonic acid has the highest affinity for ApoD so far re- 
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ported, with an association some 20-fold higher than that of 
progesterone, Interestingly, none of the metabolites of ara- 
chidonic acid that were tried showed any affinity for the pro- 
tein, which may well be because they are all generally more 
hydrophilic. The same, highly specific binding was found 
among the small series of fatty acids tried: only arachidonic 
acid showed significant binding. These factors make the rele- 
vance of this ligand in vivo all the more intriguing. 
It is tempting to speculate that the affinity of ApoD for 
arachidonic acid is the unifying factor for all of the biological 
situations where the protein is present. The eicosanoids and 
prostaglandins are formed from arachidonic acid and are in- 
volved in a wide variety of biological phenomena [27]. The 
understanding of their mechanisms ofaction is incomplete and 
suffers because of their multiple, complex and sometimes con- 
tradictory, actions. However, it is known that these compounds 
are produced locally throughout the organism in response to 
different stimuli [28], the major step-dependent factor for their 
production being the presence of the precursors, arachidonic 
acid, eicosapentanoic a id and homo-~y-linolenic a id. Ara- 
chidonic acid is stored in inactive form as phospholipids (in 
cellular membranes and in lipoproteins), triglycerides (only in 
the renal medulla) and as cholesteryl-ester (in lipoproteins). 
The release of arachidonic acid from these inactive forms de- 
pends mainly upon the regulation of the activity of phospholi- 
pases A2 and C on the membrane phospholipids and of LCAT 
in HDL, although this latter role in the metabolism of the acid 
is still unclear. 
Through its association with LCAT, ApoD may therefore 
play a role in regulating metabolism of arachidonic acid in 
lipoproteins. LCAT is known to act both as a phospholipase 
and as an esterase [29,30] with the combination of these activ- 
ities resulting in the synthesis of fatty acid cholesteryl-ester 
from cholesterol and phosphatidyl-choline. ApoD could scav- 
enge arachidonic acid thus preventing its further conversion to 
cholesterol ester. 
Another aspect of the affinity shown between ApoD and 
arachidonic acid, is related to their involvement in growth and 
regeneration processes which forsees a possible role for the 
protein in these processes. It is known that arachidonic acid 
metabolism is directly connected to cyclic-AMP formation [31] 
in, for example, sensitization to pain, the activity of nervous 
cells and cell proliferation. ApoD, on the other hand, is over- 
expressing during regeneration of peripheral rat nerve with 
maximum expression being attained 2-3 weeks after injury 
when active myelination is occurring [10]. Further, over-expres- 
sion is seen during the non-growth stages of several, particu- 
larly cancerous, cell lines [11 14]. Thus, ApoD could be acting 
as a carrier of arachidonic acid, removing this active precursor 
from the cell when division or growth is slowing down. 
In conclusion, we propose that the strong specificity of 
ApoD for arachidonic acid implies a role for this protein in the 
control of levels of this important metabolite and hence in cell 
regulation [17]. The understanding of its exact role requires 
further work. 
Acknowledgements: The authors are grateful to the EC for financial 
support under the Biotechnology Action Plan, to CICYT-Spain 
(SAL91-0617), to the Science and Engineering Research Council 
(SERC) for providing additional support, to Dr. D.T.F. Dryden for 
help with the fluorescence experiments, o Drs. N.C. Price and S. Kelly 
at the SERC CD facility in Stirling. 
56 J.H. Morais Cabral et al./FEBS Letters 366 (1995) 53-56 
References 
[1] Drayna, D., Fielding, C., McLean, J., Baer, B., Castro, G., Chen, 
E., Comstock, L., Henzel, W., Kohr, N., Rhee, L., Wion, K. and 
Lawn, R. (1986) J. Biol. Chem. 261, 16535-16539. 
[2] Pervaiz, S. and Brew, K. (1987) FASEB J. 1,209-214. 
[3] Flower, D.R., North, A.C.T. and Attwood, T.K. (1993) Protein 
Sci. 2, 753-761. 
[4] Fielding, P.E. and Fielding, C.J. (1980) Proc. Natl. Acad. Sci. USA 
77, 3327-3330. 
[5] Albers, J.J., Cheng, M.C., Ewens, S.L. and Tollefson, J.H. (1981) 
Atherosclerosis 39, 395-409. 
[6] Balbin, M., Freije, J.M.P., Fueyo, A., S~inchez, L.M. and L6pez- 
Otin, C. (1990) Biochem. J. 271,803-807. 
[7] Bradlow, H.L., Rosenfeld, R.S., Kream, J., Fleisher, M., 
O'Connor, J. and Schwartz, M.K. (1981) Cancer Res. 41,105 107. 
[8] Lea, O. (1988) Steroids 52, 337 338. 
[9] Dilley, W.G., Haagensen, D.E., Cox, C.E. and Wells Jr., S.A. 
(1990) Breast Cancer Res. Treatment 16, 253-260. 
[10] Boyles, J.K., Notterpek, L.M. and Anderson, L.J. (1990) J. Biol. 
Chem. 265, 17805-17815. 
[11] Simard, J., Dauvois, S., Haagensen, D.E., Lev6sque, C., M6raud, 
Y. and Labrie, E (1990) Endocrinology 126, 3223 3231. 
[12] Labrie, F., Simard, J., Poulin, R., Hatton, A.-C., Labrie, C., 
Dauvois, S., Zhao, H., Petitclerc, L., Couet, J., Dumont, M. and 
Haagensen Jr., D.E. (1990) Ann. N.Y. Acad. Sci. 586, 174-187. 
[13] Haagensen, D.E., Stewart, P., Dilley, W.G. and Wells, S.A. (1992) 
Breast Cancer Res. Treatment 23, 77 86. 
[14] Simard, J., Veilleux, R., de Lauvoit, Y., Haagensen, D.E. and 
Labrie, F. (1991) Cancer Res. 51, 4336-4341. 
[15] Provost, ER., Marcel, Y.U, Milne, R.W., Weech, P.K. and 
Rassart, E. (1991) FEBS Lett. 290, 139-141. 
[16] Milne, R.W., Rassart, E. and Marcel, Y.L. (1993) Curr. Opin. 
Lipidology 4, 101~106. 
[17] Flower, D.R. (1994) FEBS Lett. 354m 7 11. 
[18] McConathy, W.J. and Alaupovic, P. (1973) FEBS Lett. 37, 178 
182. 
[19] Birdsall, B., King, R.W., Whoeler, M.R., Lewis Jr., C.A., Goode, 
S.R., Dunlap, R.B. and Roberts, G.C.K. (1983) Anal. Biochem. 
132, 353 361. 
[20] Gill, S.C. and von Hippel, EH. (1989) Anal. Biochem. 182, 319 
326. 
[21] Wilson, N.H. and Jones, R.L. (1985)Thromboxane L ukotriene 
Res. 14, 393-425. 
[22] Dufour, E. and Haertl6, T. (1990) Protein Eng. 4, 185-190. 
[23] Provencher, S.W. and G16ckner, J. (1981) Biochemistry 20, 33-37. 
[24] Glatz, J.F.C. and Veerkamp, J.H. (1983) Anal. Biochem. 132, 
89 95. 
[25] Futterman, S. and Heller, J. (1972) J. Biol. Chem. 247, 5168 5172. 
[26] Dufour, E., Marden, M.C. and Haertl6, T. (1990) FEBS Lett. 277, 
223-226. 
[27] von Euler, U.S. (1988) in: Prostaglandins, Biology and Chemistry 
of Prostaglandins and Related Eicosanoids, (Curtis-Prior, EB. 
Ed.), Churchill-Livingstone, pp. 1-7. 
[28] Deby, C. (1988) in: Prostaglandins, Biology and Chemistry of 
Prostaglandins and Related Eicosanoids, (Curtis-Prior, P.B., Ed.) 
Churchill-Livingstone, pp. 11 36. 
[29] Kitakabe, K., Piran, U., Kamio, Y., Doi, Y. and Nishida, T. (1979) 
Biochim. Biophys. Acta 573, 145-154. 
[30] Francone, O.L., Evangelista, L. and Fielding, C.J. (1993) Biochim. 
Biophys. Acta 1166, 301-304. 
[31] Lagarde, M. (1988) in: Prostaglandins, Biology and Chemistry of 
Prostaglandins and Related Eicosanoids, (Curtis-Prior, P.B. Ed.) 
Churchill-Livingstone, pp. 147 151. 
